KDR and breast carcinoma: In breast cancer (BC), an anti‐α9‐nAChR/methoxy‐polyethylene glycol (mPEG)‐conjugated bispecific antibody (α9 BsAb) inhibits the expression of VEGF‐A, p‐VEGFR2, VEGFR2, and MMP9, thereby suppressing cell migration [35].